Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

733 ARTÍCULOS , VIENDO DEL 466 AL 480

Peptide-Based Therapeutics for Alzheimer's Disease: Medicinal Chemistry, AI-Guided Computational Design, and Blood-Brain Barrier Delivery

Al Khzem AH, Gomaa MS.

Drug Des Devel Ther. 2026 Apr 13;20:597087. doi: 10.2147/DDDT.S597087. eCollection 2026.

From pathology to precision therapy: Contemporary and emerging strategies in Alzheimer's disease treatment

Belavadi S, Kadiri SK.

Eur J Pharmacol. 2026 May 28;1025:178913. doi: 10.1016/j.ejphar.2026.178913. Epub 2026 Apr 29.

Neuropeptides in the Management of Alzheimer's Disease: From Pathophysiology to Therapeutic Opportunities

Tiwari S, Yadav SK, Kumari M, Dhakal T, Puranik N.

Int J Mol Sci. 2026 Apr 1;27(7):3206. doi: 10.3390/ijms27073206.

The interplay between mitophagy and ferroptosis in Alzheimer's disease: Mechanisms and therapeutic implications

Liu A, Xing L, Li J, Yao M, Song J, Guo W, Duan P, Li H.

J Alzheimers Dis. 2026 Apr;110(3):1022-1037. doi: 10.1177/13872877261420211. Epub 2026 Mar 13.

Inhaled General Anesthetics in Alzheimer's Disease Progression: Divergent Effects, Underlying Mechanisms, and Future Perspectives

Yang L, Song G, Parker E, Yang L.

Mol Neurobiol. 2026 Mar 31;63(1):542. doi: 10.1007/s12035-026-05832-w.

Mechanistic Investigation of Exercise Interventions in Rodent Models of Alzheimer's Disease and Prospects for Clinical Translation

Peng T, Zhang Z, Ding N, Zhang J.

Neural Plast. 2026;2026(1):e6718671. doi: 10.1155/np/6718671.

Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease

Vijverberg EGB, Scharre DW, Woodward M, Catalano S, Hamby ME, Grundman M, Morgan RE, Iaci J, Devins T, Caggiano AO.

J Alzheimers Dis. 2026 May;111(2):897-908. doi: 10.1177/13872877261437145. Epub 2026 Apr 3.

Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence

Qi L, Zheng F, Tu M, Abdullah R, Zhao Y, Su X, Zhou D, Peng G.

J Prev Alzheimers Dis. 2026 Mar;13(3):100473. doi: 10.1016/j.tjpad.2025.100473. Epub 2026 Jan 1.

Advances in the drug treatment of Alzheimer's disease: pathophysiology and mechanisms of action

Nowell J, Crook H, de Leon MJ, Edison P.

BMJ. 2026 Apr 20;393:78881. doi: 10.1136/bmj-2023-078881.

The role and therapeutic potential of DNA glycosylases in Alzheimer's disease

Zhao X, Li Y, Meng Z, Xu X, Chen L, Yu Q, Wang R, Ren Y, Chen F, Ai Q, Deng Y, Yu H, Wei J, Liang G.

Ageing Res Rev. 2026 Jun;118:103129. doi: 10.1016/j.arr.2026.103129. Epub 2026 Apr 10.

Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1(Glu280Ala) mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial

Tariot PN, Lopera FS, Ríos-Romenets S, Sink KM, Giraldo-Chica M, Acosta-Baena N, Villegas G, Espinosa A, Castaño ML, Muñoz C, Ospina P, Bocanegra Y, Tirado V, Henao E, Cardona E, Luna E, Lopez H, Sánchez G, Collazos MM, Alvarez S, Aguillón D, Hu N, Clayton D, Bittner T, Schneider A, Dolton M, Poon V, Nguyen J, Thomas RG, Schneider LS, Chen K, Su Y, Alexander RC, Quiroz YT, Cai Y, Xu YR, Ostaszewski B, Selkoe DJ, Ashton NJ, Denkinger MN, Jakimovich LJ, Doody RS, Langbaum JB, Reiman EM.

Lancet Neurol. 2026 Feb;25(2):147-159. doi: 10.1016/S1474-4422(25)00426-0.

Elucidating the molecular targets in Alzheimer's disease: Advances and therapeutic implications

Soni U, Pujari R.

Prog Neuropsychopharmacol Biol Psychiatry. 2026 Apr 2;146:111660. doi: 10.1016/j.pnpbp.2026.111660. Epub 2026 Mar 6.

Natural Chiral Scaffolds in Alzheimer's Disease: Therapeutic Potential, Mechanism, and Clinical Aspects

Singh A, Sahu SK, Sah AK.

Biomed Res Int. 2026;2026(1):e5968529. doi: 10.1155/bmri/5968529.

Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges

Qudoos MA, Elliott DP.

Sr Care Pharm. 2026 Apr 1;41(3):98-108. doi: 10.4140/TCP.n.2026.98.

Overcoming the blood‒brain barrier: nanomedicine strategies for targeted delivery and multimodal therapy in Alzheimer's disease

Li J, Guo L, Cai W, Mei J, Liu J, Liu Y.

Drug Deliv. 2026 Dec 31;33(1):2645830. doi: 10.1080/10717544.2026.2645830. Epub 2026 Mar 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias